Skip to main content

Most Popular

EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management

Sep 24, 2020

In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.

Read Article

Ustekinumab Early Risk for Cardiovascular Events

Sep 23, 2020

JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.

Read Article

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

Oct 15, 2020

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had

Read Article

Tofacitinib and Thromboembolic Risk

Oct 13, 2020

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m

Read Article

Novel Biologic Promising in Mid-Stage Scleroderma Trial

Sep 29, 2020

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.

Read Article

Defining Difficult Rheumatoid Arthritis

Oct 01, 2020

‘Difficult-to-treat RA’ is an oft-used term that carries various clinical qualities and therapeutic disappointments.

Read Article

RheumNow Podcast – Function Follows Form (10.2.20)

Oct 01, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. 

Read Article

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Oct 08, 2020

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Biologics Beneficial in Eosinophilic Vasculitis

MedPage Today
Oct 08, 2020

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.

Read Article

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

Oct 11, 2020

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)  and that risk is linked to RA disease activity. 

Read Article

CDC Reverses Guidance for Asymptomatic COVID Contacts

Sep 22, 2020

Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.

Read Article

COVID Transmission from Young to Old

Oct 13, 2020

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Read Article

Fractures from Delays in Denosumab Reinfusions

Oct 07, 2020

Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t

Read Article

TNF Inhibitors or non-TNF Biologics - First Best Choice?

Oct 18, 2020

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

Read Article

Low Risk of Latent TB with Secukinumab

Oct 01, 2020

TB reactivation and latent tuberculosis infection (LTBI) are warned against with biologic agents, especially TNF inhibitors; yet clinical trial data now shows that the risk of LTBI with IL-17 inhibition via secukinumab is uncommon.

Read Article

Systemic Steroids Reduce Mortality in COVID-19

Oct 06, 2020

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

Read Article

Filgotinib Approved by the EMA for Rheumatoid Arthritis

Sep 27, 2020

On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inad

Read Article

Sustained Remission Off Therapy Unlikely in GPA

Oct 08, 2020

A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.

Read Article

IL-1 Inhibition Alters Arthroplasty Rates

Oct 07, 2020

A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.

Read Article
×